Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.
Franco F, Carcereny E, Guirado M, Ortega AL, López-Castro R, Rodríguez-Abreu D, García-Campelo R, Del Barco E, Juan O, Aparisi F, González-Larriba JL, Domine M, Trigo JM, Cobo M, Cerezo S, Calzas J, Massutí B, Bosch-Barrera J, García Coves P, Domènech M, Provencio M. Franco F, et al. PLoS One. 2021 Jun 2;16(6):e0251761. doi: 10.1371/journal.pone.0251761. eCollection 2021. PLoS One. 2021. PMID: 34077442 Free PMC article.
Silibinin is a suppressor of the metastasis-promoting transcription factor ID3.
Verdura S, Encinar JA, Gratchev A, Llop-Hernández À, López J, Serrano-Hervás E, Teixidor E, López-Bonet E, Martin-Castillo B, Micol V, Bosch-Barrera J, Cuyàs E, Menendez JA. Verdura S, et al. Phytomedicine. 2024 Jun;128:155493. doi: 10.1016/j.phymed.2024.155493. Epub 2024 Mar 6. Phytomedicine. 2024. PMID: 38484626 Free article.
The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience.
Bosch-Barrera J, García-Franco C, Guillén-Grima F, Moreno-Jiménez M, López-Picazo JM, Gúrpide A, Pérez-Gracia JL, Aristu J, Torre W, García-Foncillas J, Gil-Bazo I. Bosch-Barrera J, et al. Clin Transl Oncol. 2012 Nov;14(11):835-41. doi: 10.1007/s12094-012-0874-3. Epub 2012 Jul 20. Clin Transl Oncol. 2012. PMID: 22855163
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. Karachaliou N, et al. Sci Rep. 2015 Dec 7;5:17499. doi: 10.1038/srep17499. Sci Rep. 2015. PMID: 26639561 Free PMC article.
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R. Moran T, et al. Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22. Lung Cancer. 2017. PMID: 28625629 Clinical Trial.
Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R. Morán T, et al. Oncotarget. 2018 Jun 5;9(43):27074-27086. doi: 10.18632/oncotarget.25478. eCollection 2018 Jun 5. Oncotarget. 2018. PMID: 29930751 Free PMC article.
Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R. Morán T, et al. Oncotarget. 2019 Apr 2;10(26):2576. doi: 10.18632/oncotarget.26855. eCollection 2019 Apr 2. Oncotarget. 2019. PMID: 31069018 Free PMC article.
132 results